As the weather turns warmer, women who love beauty have put weight loss on their agenda, but exercise has hurt their legs and dieting has stifled their mouths. "One needle a week, one month thin," has become the ultimate dream of many people who lose weight while swinging and weighing ×× "Jin" hypoglycemic drug Smegglutide has been hailed as a magic lamp on the bumpy road to weight loss. But can hypoglycemic drugs really reduce weight? Can people with no blood sugar problems also use it? Let's listen to Zeng Tianshu, the chief physician of endocrinology expert at Wuhan Union Medical College Hospital. Type 2 diabetes medicine has become a star drug for weight loss. In recent years, managing weight well is not only the demand of beauty lovers, but also the key to prevent obesity related chronic diseases. For people who have developed chronic diseases related to obesity, weight loss is even more urgent. Although everyone understands that good diet, exercise habits, and regular living are the most important foundations for maintaining health, it is very difficult to truly do so. In this situation, more people often hope that there is a magic drug that can easily solve the problem of obesity once and for all. In recent years, a class of drugs has become popular in the field of weight loss. This is the glucagon like peptide-1 (GLP-1) class of drugs, especially the drug Smegglutide, which has caused a weight loss craze over the past year. Many beauty lovers are flocking to it, and even medical and beauty bloggers have contributed to it. But there is a problem. So far, the instructions of GLP-1 drugs in China only indicate that they are used for the treatment of type 2 diabetes. How does it achieve the effect of weight loss? GLP-1 is a naturally secreted "enterotropin" in the human body, which can bind to receptors on islet cells and stimulate insulin secretion, thereby reducing blood sugar. It also acts on the central appetite system, reducing food intake and delaying gastric emptying. Simply put, it creates a sense of fullness, inhibits appetite, and naturally achieves weight loss. In fact, there are many hypoglycemic drugs that have certain weight loss effects, such as metformin. However, from the perspective of drug regulation, certain conditions must be met in order to include a weight loss indication on the drug leaflet. By the end of 2022, the United States Food and Drug Administration (FDA) had approved six weight loss drugs, namely, clokaserin, fentanyl topiramate compound preparations, naltrexone bupropion compound preparations, and orlistat, liraglutide, and smeglutide. The first three drugs mainly act on the central nervous system to suppress the appetite of patients, thereby achieving the effect of drug dieting to reduce weight, but with relatively large side effects. Ollistat acts on the digestive tract to inhibit fat absorption, with a relatively weak effect, and is prone to cause gastrointestinal reactions such as diarrhea, causing inconvenience to patients. Lilalutide and smeglutide are well-known drugs for type 2 diabetes. Can it be used without blood sugar problems? China's drug regulatory department has not approved! The study on adolescent obesity published in the New England Journal of Medicine in 2020 expanded the use of this drug for weight loss. These research results have led to the approval of rilalutide by drug regulatory agencies in multiple countries or regions for long-term weight loss treatment in obese adults and adolescents. And as a Lila